Literature DB >> 27256159

Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss.

Silvia Stacchiotti1, Annalisa Astolfi2, Alessandro Gronchi3, Andrea Fontana3, Maria A Pantaleo4, Tiziana Negri5, Monica Brenca6, Marcella Tazzari7, Milena Urbini2, Valentina Indio2, Chiara Colombo3, Stefano Radaelli3, Silvia Brich8, Angelo P Dei Tos9, Paolo G Casali1, Chiara Castelli7, Gian Paolo Dagrada5, Silvana Pilotti5, Roberta Maestro6.   

Abstract

UNLABELLED: Dermatofibrosarcoma protuberans (DFSP) is a rare and indolent cutaneous sarcoma. At times, a fibrosarcomatous transformation marked by a more aggressive clinical behavior may be present. We investigated the natural history and the molecular bases of progression from classic DFSP to the fibrosarcomatous form (FS-DFSP), looking, retrospectively, at the outcome of all patients affected by primary DFSP treated at our institution from 1993 to 2012 and analyzing the molecular profile of 5 DFSPs and 5 FS-DFSPs by an integrated genomics approach (whole transcriptome sequencing, copy number analysis, FISH, qRT-PCR, IHC). The presence of fibrosarcomatous features was identified in 20 (7.6%) patients out of 263 DFSP. All cases were treated with macroscopic complete surgery. A local relapse occurred in 4 of 23 patients who received a microscopic marginal surgery (2 classic DFSP, 2 FS-DFSP), while metastasis affected 2 patients, both FS-DFSP (10% of FS-DFSP), being the first event. DFSP evolution to FS-DFSP was paralleled by a transcriptional reprogramming. The recurrent loss of chromosome 22q appeared to contribute to this phenomenon by promoting the expression of epigenetic regulators, such as EZH2. Loss of the p16/CDKN2A/INK4A locus at 9p was also observed in two FS-DFSP metastatic cases. IMPLICATIONS: FS-DFSP is a rare subgroup among DFSP, with a 10% metastatic risk, that was independent from local recurrence and that was not observed in DFSP, that were all cured by wide surgery. Chromosome 22q deletion might play a role in FS-DFSP, and p16 loss may convey a poor outcome. EZH2 dysregulation was also found and represents a druggable target. Mol Cancer Res; 14(9); 820-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27256159     DOI: 10.1158/1541-7786.MCR-16-0068

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  10 in total

Review 1.  Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Authors:  Takeshi Iwasaki; Hidetaka Yamamoto; Yoshinao Oda
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

2.  Coamplification of 12q15 and 12p13 and homozygous CDKN2A/2B deletion: synergistic role of fibrosarcomatous transformation in dermatofibrosarcoma protuberans with a cryptic COL1A1-PDGFB fusion.

Authors:  Yang Lu; Tao Li; Min Chen; Heng Peng; Tianhai Du; Yan Qiu; Hongying Zhang
Journal:  Virchows Arch       Date:  2022-02-16       Impact factor: 4.535

3.  Dermatofibrosarcoma protuberance in a black African cohort-a clinicopathologic study.

Authors:  Gabriel Olabiyi Ogun; Uchenna Simon Ezenkwa; Omobolaji Oladayo Ayandipo
Journal:  Ecancermedicalscience       Date:  2020-08-07

4.  Clinical Features, Pathological Findings and Treatment of Recurrent Dermatofibrosarcoma Protuberans.

Authors:  Yanan Li; Chuan Wang; Bo Xiang; Siyuan Chen; Li Li; Yi Ji
Journal:  J Cancer       Date:  2017-05-12       Impact factor: 4.207

5.  EGFR is involved in dermatofibrosarcoma protuberans progression to high grade sarcoma.

Authors:  Amélie Osio; Shuo Xu; Morad El Bouchtaoui; Christophe Leboeuf; Guillaume Gapihan; Christine Lemaignan; Guilhem Bousquet; Céleste Lebbé; Anne Janin; Maxime Battistella
Journal:  Oncotarget       Date:  2018-01-03

Review 6.  The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.

Authors:  Malumani Malan; Wu Xuejingzi; Song Ji Quan
Journal:  Pan Afr Med J       Date:  2019-08-13

7.  Clinicopathological features of fibrosarcomatous dermatofibrosarcoma protuberans and the construction of a back-propagation neural network recognition model.

Authors:  Yanan Li; Jiaqi Liang; Xuewen Xu; Xian Jiang; Chuan Wang; Siyuan Chen; Bo Xiang; Yi Ji
Journal:  Orphanet J Rare Dis       Date:  2021-01-26       Impact factor: 4.123

Review 8.  Epigenetics of Cutaneous Sarcoma.

Authors:  Emi Mashima; Yu Sawada
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

9.  Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.

Authors:  Kenji Tsuchihashi; Hitoshi Kusaba; Yuichi Yamada; Yuta Okumura; Hozumi Shimokawa; Masato Komoda; Keita Uchino; Tomoyasu Yoshihiro; Nobuhiro Tsuruta; Fumiyasu Hanamura; Kyoko Inadomi; Mamoru Ito; Kosuke Sagara; Michitaka Nakano; Kenta Nio; Shuji Arita; Hiroshi Ariyama; Kenichi Kohashi; Ryuji Tominaga; Yoshinao Oda; Koichi Akashi; Eishi Baba
Journal:  Mol Clin Oncol       Date:  2017-03-17

10.  Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans.

Authors:  Ensel Oh; Hae Min Jeong; Mi Jeong Kwon; Sang Yun Ha; Hyung Kyu Park; Ji-Young Song; Yu Jin Kim; Jong-Sun Choi; Eun Hee Lee; Jeeyun Lee; Yoon-La Choi; Young Kee Shin
Journal:  PLoS One       Date:  2017-10-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.